Table 2.

JAK2V617F VAF in prospective PV clinical trials

Conventional riskAge (y)Disease duration (y)Previous cytoreductive
(%)		Thrombosis
(%)		WBC,
×109/L		Median JAK2V617F VAF (%)
LOW-PV61  Low 50 <2 0 0 10 35 
PROUD-PV62  Low and high 60 <2 30 20 10 42 
RESPONSE-263  High 65 6 100 26 12 53 
RESPONSE-13  High 61 8 100 30 18 76 
Conventional riskAge (y)Disease duration (y)Previous cytoreductive
(%)		Thrombosis
(%)		WBC,
×109/L		Median JAK2V617F VAF (%)
LOW-PV61  Low 50 <2 0 0 10 35 
PROUD-PV62  Low and high 60 <2 30 20 10 42 
RESPONSE-263  High 65 6 100 26 12 53 
RESPONSE-13  High 61 8 100 30 18 76 

WBC, white blood cell count.

View Large